Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity [On My Mind]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - November 14, 2017 Category: Cardiology Authors: DeFilippis, E. M., Butler, J., Vaduganathan, M. Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Sudden Cardiac Death, Cardiomyopathy, Heart Failure On My Mind Source Type: research
Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings [Original Article]
Conclusions
In recent years, there have been substantial changes in the epidemiology of HF in Medicare beneficiaries, with a decline in incident HF and a decrease in 1-year HF mortality, whereas the overall burden of HF continues to increase. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - November 12, 2017 Category: Cardiology Authors: Khera, R., Pandey, A., Ayers, C. R., Agusala, V., Pruitt, S. L., Halm, E. A., Drazner, M. H., Das, S. R., de Lemos, J. A., Berry, J. D. Tags: Epidemiology, Heart Failure, Health Services, Quality and Outcomes Original Article Source Type: research
Sildenafil Is Associated With Reduced Device Thrombosis and Ischemic Stroke Despite Low-Level Hemolysis on Heart Mate II Support [Original Articles]
Conclusions:
Sildenafil is associated with reduced device thrombosis and ischemic stroke during ongoing LLH on Heart Mate II support. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - November 1, 2017 Category: Cardiology Authors: Saeed, O., Rangasamy, S., Selevany, I., Madan, S., Fertel, J., Eisenberg, R., Aljoudi, M., Patel, S. R., Shin, J., Sims, D. B., Reyes Gil, M., Goldstein, D. J., Slepian, M. J., Billett, H. H., Jorde, U. P. Tags: Cardiomyopathy, Heart Failure, Ischemic Stroke Original Articles Source Type: research
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients--An Analysis From 5 Clinical Trials [Original Articles]
Conclusions:
There is marked heterogeneity of treatment benefit of CRT that can be predicted based on baseline QoL, age, and QRS duration. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 16, 2017 Category: Cardiology Authors: Nassif, M. E., Tang, Y., Cleland, J. G., Abraham, W. T., Linde, C., Gold, M. R., Young, J. B., Daubert, J. C., Sherfesee, L., Schaber, D., Tang, A. S. L., Jones, P. G., Arnold, S. V., Spertus, J. A. Tags: Heart Failure, Quality and Outcomes Original Articles Source Type: research
Response by Andreas et al to Letter Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial" [Correspondence]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 13, 2017 Category: Cardiology Authors: Andreas, M., Moayedifar, R., Wieselthaler, G., Wolzt, M., Riebandt, J., Haberl, T., Angleitner, P., Schloglhofer, T., Wiedemann, D., Schima, H., Laufer, G., Zimpfer, D. Tags: Cardiomyopathy, Heart Failure, Anticoagulants, Cardiovascular Surgery Correspondence Source Type: research
Letter by Heinrich-Nols and Kreuzer Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial" [Correspondence]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 13, 2017 Category: Cardiology Authors: Heinrich-Nols, J., Kreuzer, J. Tags: Anticoagulants Correspondence Source Type: research
Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium [Original Articles]
Conclusions:
Our findings demonstrate that OM augments force generation but also prolongs the time course of XB transitions to force-bearing states in remodeled HF myocardium, which may extend the systolic ejection time in vivo. Optimal OM dosing is critical for eliciting enhanced systolic function without excessive prolongation of systolic ejection time, which may compromise diastolic filling. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 13, 2017 Category: Cardiology Authors: Mamidi, R., Li, J., Gresham, K. S., Verma, S., Doh, C. Y., Li, A., Lal, S., dos Remedios, C. G., Stelzer, J. E. Tags: Heart Failure Original Articles Source Type: research
Patient and Spousal Health and Outcomes in Heart Failure [Original Articles]
Conclusions:
We found no evidence that the health of a spouse impacts patient outcomes after HF diagnosis. However, after a patient with HF dies, their surviving spouse’s risk of hospitalization and death increases. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 13, 2017 Category: Cardiology Authors: Dunlay, S. M., Roger, V. L., Weston, S. A., Bangerter, L. R., Killian, J. M., Griffin, J. M. Tags: Epidemiology, Heart Failure, Mortality/Survival Original Articles Source Type: research
Is the Way to Someones Heart Through Their Stomach?: The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure [On My Mind]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 11, 2017 Category: Cardiology Authors: Packer, M. Tags: Heart Failure, Metabolic Syndrome On My Mind Source Type: research
Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3-Targeted Knockin Mice [Original Articles]
Conclusions:
Altogether, we found that (1) autophagy is altered in patients with HCM carrying MYBPC3 mutations, (2) autophagy is impaired in Mybpc3-targeted knockin mice, and (3) activation of autophagy ameliorated the cardiac disease phenotype in this mouse model. We propose that activation of autophagy might be an attractive option alone or in combination with another therapy to rescue HCM caused by MYBPC3 mutations. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 11, 2017 Category: Cardiology Authors: Singh, S. R., Zech, A. T. L., Geertz, B., Reischmann-Dusener, S., Osinska, H., Prondzynski, M., Kramer, E., Meng, Q., Redwood, C., van der Velden, J., Robbins, J., Schlossarek, S., Carrier, L. Tags: Animal Models of Human Disease, Cell Signaling/Signal Transduction, Heart Failure, Hypertrophy Original Articles Source Type: research
Early Right Ventricular Assist Device Use in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation: Incidence and Risk Factors From the Interagency Registry for Mechanically Assisted Circulatory Support [Original Articles]
Conclusions:
The need for RVAD implantation after LVAD is associated with indices of global illness severity, markers of end-organ dysfunction, and profiles of hemodynamic instability. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 11, 2017 Category: Cardiology Authors: Kiernan, M. S., Grandin, E. W., Brinkley, M., Kapur, N. K., Pham, D. T., Ruthazer, R., Rame, J. E., Atluri, P., Birati, E. Y., Oliveira, G. H., Pagani, F. D., Kirklin, J. K., Naftel, D., Kormos, R. L., Teuteberg, J. J., DeNofrio, D. Tags: Heart Failure, Cardiovascular Surgery Original Articles Source Type: research
Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation [Editorial]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 10, 2017 Category: Cardiology Authors: Voors, A. A., Lam, C. S. P. Tags: Heart Failure Editorial Source Type: research
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation [Original Articles]
Conclusions
HF and reduced ejection fraction patients with AF had higher NT-proBNP than those without AF. However, above a concentration of 400 pg/mL (representing most patients in each group), NT-proBNP had similar predictive value for adverse cardiovascular outcomes, irrespective of AF status.
Clinical Trial Registration
URL: https://www.clinicaltrials.gov. Unique identifier NCT00853658 (ATMOSPHERE) and NCT01035255 (PARADIGM-HF). (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - October 10, 2017 Category: Cardiology Authors: Kristensen, S. L., Jhund, P. S., Mogensen, U. M., Rorth, R., Abraham, W. T., Desai, A., Dickstein, K., Rouleau, J. L., Zile, M. R., Swedberg, K., Packer, M., Solomon, S. D., Kober, L., McMurray, J. J. V., on behalf of the PARADIGM-HF and ATMOSPHERE Commit Tags: Heart Failure, Prognosis Original Articles Source Type: research
Editors Perspective [Editor's Perspective]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - September 14, 2017 Category: Cardiology Authors: Sweitzer, N. K. Tags: Heart Failure Editor ' s Perspective Source Type: research
What We Talk About When We Talk About the Wedge Pressure [Editorial]
(Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - September 14, 2017 Category: Cardiology Authors: Houston, B. A., Tedford, R. J. Tags: Pulmonary Hypertension Editorial Source Type: research
